In achieving double-digit growth in both net income and margins, and in the development of new pharmaceutical products to be launched in the EU. and in the US, the pharmaceutical company Pharmathen, which recorded an increase in all its financial indicators last year, is aiming for the next period. In a landmark year for Pharmathen, following its sale by BC Partners to a Swiss private equity partner group for €1.6 billion, turnover (PHARMATEN ABEE) increased by 2% to €232.4 million from €227.2 million last year year. 2020, mainly due to an increase in sales of 5.2 million euros in 2021. worldwide marketing of generic pharmaceutical products.

As a group, it develops an average of 10 generic products each year, has about 300 customers, and exports to 90 countries, with its exports accounting for about 95% of total sales. As such, 2021 also ended positively in terms of profitability, with Pharmathen grossing €79m from €71.9m in the previous year, and profit before taxes, interest and depreciation increased by 4.2% to €63.2m from 60.6 million euros in the previous year. prior year. In terms of net income (company level), it amounted to 38 million euros from 31.9 million euros in 2020 (16%). According to the published financial statements of the company, the annual growth rate of its sales over the past 5 years exceeds 10%, and EBITDA is about 27% of sales.

The turnover of the pharmaceutical industry increased by 2% to 232.4 million euros from 227.2 million euros in 2020.

Pharmathen already has two manufacturing units in Pallini and Sapes-Rhodopis and has recently increased by €50 million a five-year investment plan of €200 million (2022-2026) to establish a new center in Attica that will promote the development of LAI products, but also in technologies of ophthalmic products. The new division is expected to be completed in 2025, creating at least 150 jobs, Partners Group President Charles Dallara said last April at a meeting with Prime Minister Kyriakos Mitsotakis. The turmoil caused by the war in Ukraine and lockdowns in some Chinese cities does not seem to slow down the plans of Pharmathen, which, according to initial estimates, expects growth of more than 20% this year.

With a turnover (group level) in excess of 250 million euros, Pharmathen employs a total of over 1,200 employees whose main focus is to continue developing new products, accelerating investment in the new LAI plant, as well as launching new products in the EU. but also in the USA. It is recalled that in 2015, BC Partners acquired 80% of the pharmaceutical industry for approximately 480 million euros from the Katsu family (which remained 20% until 2021), selling the entire company 6 years later to the Swiss private equity group Partners Group for 1.6 billion euros . Euro.